Medtronic Signals Confident Growth Path in Earnings Call
Medtronic ((MDT)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Medtronic’s latest earnings call struck an upbeat tone, with management highlighting the strongest top-line performance in a decade and earnings per share comfortably ahead of expectations. While tariffs, product mix and some lagging business lines weighed on margins, executives framed these as manageable headwinds amid robust cash generation, accelerating growth platforms and disciplined investment for FY 2027.
Revenue Growth Hits Decade-High Pace
Medtronic posted Q4 revenue of $9.8 billion, up 9.9% reported and 6.6% organic, capping a year of broad-based strength. Full-year fiscal 2026 revenue reached $36.4 billion, up 8.4% reported and 5.8% organic, marking the company’s strongest top-line showing in ten years and reinforcing confidence in the durability of its growth engine.
EPS Beat and Cash Generation Strengthen Balance Sheet
Adjusted EPS landed at $1.55 for Q4 and $5.53 for FY 2026, both ahead of internal and external expectations despite incremental spending. Free cash flow came in at $5.4 billion, the best since 2022, leaving Medtronic with $9.2 billion in cash and investments and ample flexibility for M&A, venture investments and shareholder returns.
Cardiac Ablation Solutions Become a Growth Powerhouse
Cardiac Ablation Solutions surged 78% worldwide and 124% in the U.S., gaining roughly eight percentage points of domestic share as physicians embraced its new technologies. Pulsed field ablation volumes climbed about 145% globally, the Affera installed base rose 40% sequentially, and the CAS franchise is already annualizing at around $2 billion.
Renal Denervation (Symplicity) Builds Commercial Momentum
Medtronic’s Symplicity renal denervation platform is annualizing at roughly $100 million as adoption builds after coverage decisions. A physician finder now spans 200 doctors across more than 300 accounts, weekly procedure volumes have doubled since coverage, and three-year data show sustained double-digit systolic blood pressure reductions for most treated patients.
Surgical Robotics and Digital Tools Gain Traction
The Hugo robotic platform is growing procedure volumes at two to three times the global market, with a U.S. urology launch now underway and initial patients treated. Medtronic has filed for 510(k) clearance in General Surgery and GYN, while its Touch Surgery digital ecosystem surpassed 1,400 installations, up more than 30% sequentially, deepening its data and workflow footprint.
Altaviva Drives New Momentum in Pelvic Health
Altaviva is showing early commercial traction, with nearly 1,000 physicians trained since launch and active implanters tripling sequentially. Patients treated rose 2.5 times quarter-over-quarter, supported by device features such as same-day activation and up to 15 years of projected longevity, which are helping accelerate clinician adoption.
Portfolio Shaping and Targeted Deal-Making
Management continued to refine the portfolio, completing the MiniMed IPO, closing the CathWorks deal and announcing acquisitions of Scientia and SPR Therapeutics. Recent transactions, along with venture stakes in Beluga Medical and CardioACC, are expected to contribute about $150 million of inorganic revenue in FY 2027, with roughly $250 million invested across 16 venture deals last year.
Margin Expansion and Efficiency Gains Offset Some Pressure
Adjusted gross margin improved to 65.4%, up 30 basis points year over year and 50 basis points sequentially, helped by pricing and cost of goods efficiencies net of inflation. These gains supported an adjusted operating margin of 25.5% and $2.5 billion of adjusted operating profit, even as the company funded heavier commercial and R&D investments.
Structural Heart and TAVR Face Market Headwinds
Structural Heart revenue was flat in Q4, with the U.S. particularly soft as low-risk TAVR trial data weighed on procedure growth and physician behavior. Coronary also declined in the quarter, and management acknowledged the TAVR slowdown is more pronounced domestically, requiring targeted stabilization efforts to reaccelerate growth in this franchise.
Tariffs Emerge as a Material Profit Drag
Tariffs reduced Q4 gross margin by about $74 million, or roughly 80 basis points, and remain an ongoing drag on profitability entering FY 2027. Management is modeling approximately $250 million of tariff impact for the coming year and notes that additional trade actions are not assumed to be resolved, keeping tariffs a key uncertainty around future margins.
Product Mix and Diabetes Temper Margin Upside
Product mix was an unfavorable 60 basis points in Q4, driven by a higher share of capital equipment and the impact of Diabetes, which carries lower margins. Guidance assumes the full-year inclusion of the MiniMed Diabetes business, which management says dilutes margins until its separation, adding another layer of mix pressure despite strong core profitability.
Strategic Investments Lift Operating Expenses
Adjusted SG&A rose to 30.5% of revenue, up 30 basis points year over year, as Medtronic deliberately increased commercial investment behind high-growth platforms. R&D spending reached about 7% of revenue, up roughly $150 million for the year, with executives accepting near-term margin pressure to fund pipeline programs and sustain longer-term innovation.
Uneven Recovery in Bariatrics and Pelvic Health Subsegments
Certain therapy areas remain under pressure, with bariatrics cited as a continuing weak spot and Pelvic Health flat overall despite Altaviva’s growth. Softness in sacral nerve modulation offset Altaviva’s gains, underscoring that not all segments are firing in unison and that parts of the portfolio may recover more slowly than the broader company.
Geopolitics and Cost Inflation Add to the Headwinds
Management flagged geopolitical tension in the Middle East as another earnings drag, expecting about a one-point headwind from higher fuel and transportation costs. Currency and potential tariff refunds remain wildcards, with leadership opting not to bake in upside from FX or policy relief, and instead presenting guidance that leans conservative on macro variables.
MiniMed Separation Timing Creates Modeling Noise
Guidance assumes Medtronic remains majority owner of Diabetes through the year, with no benefit from a potential earlier separation on share count or earnings. Executives noted that while an earlier spin could offer upside, they are embedding about 2% dilution from recent M&A and leaving the timing and financial effects of the Diabetes separation as a key source of near-term uncertainty.
Guidance Signals Confident but Disciplined Outlook
For FY 2027, Medtronic is guiding organic revenue growth of 6.75% to 7.25%, with Q1 expected at roughly 11.5% to 12% helped by an extra selling week. Adjusted EPS is projected at $5.90 to $6.00, with operating margin up about 60 basis points despite around $250 million of modeled tariffs, roughly 2% M&A dilution, neutral-to-slightly positive FX and a one-point headwind from higher fuel and transport costs.
Management closed the call stressing that FY 2026 marked a turning point, with growth platforms like CAS, Symplicity, Hugo and Altaviva beginning to scale while cash flow and liquidity provide ample strategic freedom. For investors, Medtronic’s story is increasingly about balancing solid, visible growth with disciplined investment and risk management as it navigates tariffs, trade uncertainty and the pending Diabetes separation.
